Malignant hyperthermia when dantrolene is not readily available.
Adolescent
Adult
Aged
Arterial Pressure
Blood Coagulation Disorders
/ epidemiology
Carbon Dioxide
/ metabolism
Child
Child, Preschool
China
/ epidemiology
Creatine Kinase
/ blood
Creatine Kinase, MB Form
/ blood
Dantrolene
/ supply & distribution
Databases, Factual
Female
Humans
Hydrogen-Ion Concentration
Infant
Infant, Newborn
Male
Malignant Hyperthermia
/ epidemiology
Middle Aged
Muscle Relaxants, Central
/ supply & distribution
Myoglobin
/ blood
Potassium
/ blood
Tidal Volume
Young Adult
Dantrolene
Enzyme
Malignant hyperthermia
Mortality
Treatment
Journal
BMC anesthesiology
ISSN: 1471-2253
Titre abrégé: BMC Anesthesiol
Pays: England
ID NLM: 100968535
Informations de publication
Date de publication:
16 04 2021
16 04 2021
Historique:
received:
17
02
2021
accepted:
30
03
2021
entrez:
17
4
2021
pubmed:
18
4
2021
medline:
6
1
2022
Statut:
epublish
Résumé
Malignant hyperthermia is a rare but life-threatening pharmacogenetic muscle disorder characterized by abnormal hypermetabolic reactions and commonly triggered in susceptible individuals by volatile anesthetics or succinylcholine, or both. Unfortunately, the specific medicine dantrolene is not readily available in many countries including China. The aim of this study was to find the characteristics of malignant hyperthermia under the situation that dantrolene is not readily available. The cases of malignant hyperthermia reported on the most commonly used databases in China from 1985 to 2020 were analyzed. The inclusion criteria were the MH episodes only related to anesthesia. The exclusion criteria were dubious MH episodes only caused by Ketamine administration or MH episodes irrelevant to anesthesia. Independent samples t-test and Pearson's chi-squared test were applied to assess the difference between the survived and death cases. Ninety-two cases of malignant hyperthermia reported on the most commonly used databases in China from 1985 to 2020 were analyzed. Median (IQR [range]) age was 18.5 (11.8-37.0 [0-70.0]) years. Compared with the survived cases, the death cases had higher maximum end-tidal partial pressure of CO In countries that dantrolene is not readily available, early warning, diagnosis, and prompt effective therapies are crucial for MH patients to survive.
Sections du résumé
BACKGROUND
Malignant hyperthermia is a rare but life-threatening pharmacogenetic muscle disorder characterized by abnormal hypermetabolic reactions and commonly triggered in susceptible individuals by volatile anesthetics or succinylcholine, or both. Unfortunately, the specific medicine dantrolene is not readily available in many countries including China. The aim of this study was to find the characteristics of malignant hyperthermia under the situation that dantrolene is not readily available.
METHODS
The cases of malignant hyperthermia reported on the most commonly used databases in China from 1985 to 2020 were analyzed. The inclusion criteria were the MH episodes only related to anesthesia. The exclusion criteria were dubious MH episodes only caused by Ketamine administration or MH episodes irrelevant to anesthesia. Independent samples t-test and Pearson's chi-squared test were applied to assess the difference between the survived and death cases.
RESULTS
Ninety-two cases of malignant hyperthermia reported on the most commonly used databases in China from 1985 to 2020 were analyzed. Median (IQR [range]) age was 18.5 (11.8-37.0 [0-70.0]) years. Compared with the survived cases, the death cases had higher maximum end-tidal partial pressure of CO
CONCLUSIONS
In countries that dantrolene is not readily available, early warning, diagnosis, and prompt effective therapies are crucial for MH patients to survive.
Identifiants
pubmed: 33863282
doi: 10.1186/s12871-021-01328-3
pii: 10.1186/s12871-021-01328-3
pmc: PMC8051048
doi:
Substances chimiques
Muscle Relaxants, Central
0
Myoglobin
0
Carbon Dioxide
142M471B3J
Creatine Kinase
EC 2.7.3.2
Creatine Kinase, MB Form
EC 2.7.3.2
Dantrolene
F64QU97QCR
Potassium
RWP5GA015D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
119Références
Can Anaesth Soc J. 1970 Jul;17(4):293-315
pubmed: 4246871
Ther Clin Risk Manag. 2014 May 14;10:355-62
pubmed: 24868161
J Clin Anesth. 2017 Jun;39:10-14
pubmed: 28494877
J Craniofac Surg. 2003 Sep;14(5):800-2
pubmed: 14501352
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006 Aug;31(4):613-4
pubmed: 16951533
Orphanet J Rare Dis. 2015 Aug 04;10:93
pubmed: 26238698
Anesth Analg. 2010 Feb 1;110(2):498-507
pubmed: 20081135
Anesthesiology. 1994 Apr;80(4):771-9
pubmed: 8024130
Lancet. 1998 Oct 3;352(9134):1131-6
pubmed: 9798607
Br J Anaesth. 2009 Oct;103(4):538-48
pubmed: 19648156
Anesthesiology. 2002 Nov;97(5):1067-74
pubmed: 12411788
Anesthesiology. 2018 Jan;128(1):168-180
pubmed: 28902675
Anesthesiology. 2013 Nov;119(5):1043-53
pubmed: 24195946
Anesth Analg. 1985 Jul;64(7):700-4
pubmed: 4014731